Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

348 ARTÍCULOS , VIENDO DEL 331 AL 345

How does a woman with Alzheimer's disease make sense of becoming cared for?

Borley G, Sixsmith J, Church S.

Dementia (London). 2016 Nov;15(6):1405-1421. doi: 10.1177/1471301214561647. Epub 2014 Dec 3.

P300 Amplitude in Alzheimer's Disease: A Meta-Analysis and Meta-Regression

Hedges D, Janis R, Mickelson S, Keith C, Bennett D, Brown BL.

Clin EEG Neurosci. 2016 Jan;47(1):48-55. doi: 10.1177/1550059414550567. Epub 2014 Sep 23.

Subjective cognitive impairment: Towards early identification of Alzheimer disease

Garcia-Ptacek S, Eriksdotter M, Jelic V, Porta-Etessam J, Kåreholt I, Manzano Palomo S.

Neurologia. 2016 Oct;31(8):562-71. doi: 10.1016/j.nrl.2013.02.007. Epub 2013 Apr 17.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins

Butterfield DA, Palmieri EM, Castegna A.

Expert Rev Proteomics. 2016;13(3):259-74. doi: 10.1586/14789450.2016.1149470.

Protein Amyloidogenesis Investigated by Small Angle Scattering

Ricci C, Spinozzi F, Mariani P, Ortore MG.

Curr Pharm Des. 2016;22(26):3937-49. doi: 10.2174/1381612822666160519113237.

Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

Vemuri P, Fields J, Peter J, Klöppel S.

Curr Opin Neurol. 2016 Aug;29(4):405-11. doi: 10.1097/WCO.0000000000000346.

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti L, Eusebi P, Lleó A.

Front Neurol Neurosci. 2016;39:117-23. doi: 10.1159/000445452. Epub 2016 Jul 26.

The Significance of the Default Mode Network (DMN) in Neurological and Neuropsychiatric Disorders: A Review

Mohan A, Roberto AJ, Mohan A, Lorenzo A, Jones K, Carney MJ, Liogier-Weyback L, Hwang S, Lapidus KA.

Yale J Biol Med. 2016 Mar 24;89(1):49-57. eCollection 2016 Mar.

Positron Emission Tomography and Single-Photon Emission Computed Tomography in Neurology

Miletich RS.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1636-1654. doi: 10.1212/CON.0000000000000389.

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases

Van der Schyf CJ.

Drug Dev Res. 2016 Dec;77(8):458-468. doi: 10.1002/ddr.21368. Epub 2016 Nov 4.

Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis

Lyoo CH, Cho H, Choi JY, Hwang MS, Hong SK, Kim YJ, Ryu YH, Lee MS.

J Alzheimers Dis. 2016;51(3):671-5. doi: 10.3233/JAD-151052.

The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease

Clark LF, Kodadek T.

ACS Chem Neurosci. 2016 May 18;7(5):520-7. doi: 10.1021/acschemneuro.6b00042. Epub 2016 Apr 14.

Palmitoylation in Alzheimer's disease and other neurodegenerative diseases

Cho E, Park M.

Pharmacol Res. 2016 Sep;111:133-151. doi: 10.1016/j.phrs.2016.06.008. Epub 2016 Jun 9.

Eye movements in neurodegenerative diseases

MacAskill MR, Anderson TJ.

Curr Opin Neurol. 2016 Feb;29(1):61-8. doi: 10.1097/WCO.0000000000000274.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias